These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

420 related items for PubMed ID: 8205641

  • 1. Lessons from Cuba: mass campaign administration of trivalent oral poliovirus vaccine and seroprevalence of poliovirus neutralizing antibodies.
    Mas Lago P, Ramon Bravo J, Andrus JK, Comellas MM, Galindo MA, de Quadros CA, Bell E.
    Bull World Health Organ; 1994; 72(2):221-5. PubMed ID: 8205641
    [Abstract] [Full Text] [Related]

  • 2. Immunogenicity of oral poliovirus vaccine administered in mass campaigns versus routine immunization programmes.
    Richardson G, Linkins RW, Eames MA, Wood DJ, Campbell PJ, Ankers E, Deniel M, Kabbaj A, Magrath DI, Minor PD.
    Bull World Health Organ; 1995; 73(6):769-77. PubMed ID: 8907770
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Early immunization of neonates with trivalent oral poliovirus vaccine.
    Weckx LY, Schmidt BJ, Herrmann AA, Miyasaki CH, Novo NF.
    Bull World Health Organ; 1992; 70(1):85-91. PubMed ID: 1314711
    [Abstract] [Full Text] [Related]

  • 6. [Thermostability and immunogenicity of trivalent oral poliovirus vaccine produced by different countries].
    Kong J.
    Zhonghua Liu Xing Bing Xue Za Zhi; 1993 Jun; 14(3):151-4. PubMed ID: 8221837
    [Abstract] [Full Text] [Related]

  • 7. Two research projects seek to improve immunization practices.
    Bull Pan Am Health Organ; 1992 Jun; 26(1):96-7. PubMed ID: 1318142
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Oral iodine supplementation does not reduce neutralizing antibody responses to oral poliovirus vaccine.
    Taffs RE, Enterline JC, Rusmil K, Muhilal, Suwardi SS, Rustama D, Djatnika, Cobra C, Semba RD, Cohen N, Asher DM.
    Bull World Health Organ; 1999 Jun; 77(6):484-91. PubMed ID: 10427933
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. [Post-vaccination anti-poliomyelitis seroprevalence in an urban setting in Abidjan].
    Akoua-Koffi G, Thonnon J, Kouassi-Renaud M, Dosso M, Ehouman A.
    Bull Soc Pathol Exot; 1995 Jun; 88(3):117-20. PubMed ID: 8555765
    [Abstract] [Full Text] [Related]

  • 12. Antipolio prophylaxis of immunocompromised children during a nationwide oral poliovaccine campaign.
    Stenvik M, Hovi L, Siimes MA, Roivainen M, Hovi T.
    Pediatr Infect Dis J; 1987 Dec; 6(12):1106-10. PubMed ID: 2829105
    [Abstract] [Full Text] [Related]

  • 13. Monovalent type 1 oral poliovirus vaccine in newborns.
    el-Sayed N, el-Gamal Y, Abbassy AA, Seoud I, Salama M, Kandeel A, Hossny E, Shawky A, Hussein HA, Pallansch MA, van der Avoort HG, Burton AH, Sreevatsava M, Malankar P, Wahdan MH, Sutter RW.
    N Engl J Med; 2008 Oct 16; 359(16):1655-65. PubMed ID: 18923170
    [Abstract] [Full Text] [Related]

  • 14. Immunogenicity and safety evaluation of bivalent types 1 and 3 oral poliovirus vaccine by comparing different poliomyelitis vaccination schedules in China: A randomized controlled non-inferiority clinical trial.
    Qiu J, Yang Y, Huang L, Wang L, Jiang Z, Gong J, Wang W, Wang H, Guo S, Li C, Wei S, Mo Z, Xia J.
    Hum Vaccin Immunother; 2017 Jun 03; 13(6):1-10. PubMed ID: 28362135
    [Abstract] [Full Text] [Related]

  • 15. Trial of a supplemental dose of four poliovirus vaccines.
    Sutter RW, Suleiman AJ, Malankar P, Al-Khusaiby S, Mehta F, Clements GB, Pallansch MA, Robertson SE.
    N Engl J Med; 2000 Sep 14; 343(11):767-73. PubMed ID: 10984564
    [Abstract] [Full Text] [Related]

  • 16. Antibody persistence after primary immunization with trivalent oral poliovirus vaccine.
    Krugman RD, Hardy GE, Sellers C, Parkman PD, Witte JJ, Meyer BC, Meyer HM.
    Pediatrics; 1977 Jul 14; 60(1):80-2. PubMed ID: 195265
    [Abstract] [Full Text] [Related]

  • 17. Immunogenicity of bivalent types 1 and 3 oral poliovirus vaccine: a randomised, double-blind, controlled trial.
    Sutter RW, John TJ, Jain H, Agarkhedkar S, Ramanan PV, Verma H, Deshpande J, Singh AP, Sreevatsava M, Malankar P, Burton A, Chatterjee A, Jafari H, Aylward RB.
    Lancet; 2010 Nov 13; 376(9753):1682-8. PubMed ID: 20980048
    [Abstract] [Full Text] [Related]

  • 18. Randomized trial of type 1 and type 3 oral monovalent poliovirus vaccines in newborns in Africa.
    Waggie Z, Geldenhuys H, Sutter RW, Jacks M, Mulenga H, Mahomed H, De Kock M, Hanekom W, Pallansch MA, Kahn AL, Burton AH, Sreevatsava M, Hussey G.
    J Infect Dis; 2012 Jan 15; 205(2):228-36. PubMed ID: 22158680
    [Abstract] [Full Text] [Related]

  • 19. Monovalent type 1 oral poliovirus vaccine among infants in India: report of two randomized double-blind controlled clinical trials.
    John TJ, Jain H, Ravishankar K, Amaresh A, Verma H, Deshpande J, Pallansch MA, Singh AP, Sreevatsava M, Burton A, Malankar P, Chatterjee A, Sutter RW.
    Vaccine; 2011 Aug 05; 29(34):5793-801. PubMed ID: 21641951
    [Abstract] [Full Text] [Related]

  • 20. Immunogenicity of supplemental doses of poliovirus vaccine for children aged 6-9 months in Moradabad, India: a community-based, randomised controlled trial.
    Estívariz CF, Jafari H, Sutter RW, John TJ, Jain V, Agarwal A, Verma H, Pallansch MA, Singh AP, Guirguis S, Awale J, Burton A, Bahl S, Chatterjee A, Aylward RB.
    Lancet Infect Dis; 2012 Feb 05; 12(2):128-35. PubMed ID: 22071249
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.